Brazil tears up Abbott deal, threatens to violate Kaletra patent

Brazil is again threatening to break Abbott's patent on Kaletra if it won't offer the country a deeper discount on the AIDS drug. Several Brazilian labs have reported to the government that they can manufacture and sell Kaletra for 41 cents per pill, far less than the $1.17 per pill that Abbott charges. A spokesperson for Abbott said the company had thought that it had already struck a fair deal to discount Kaletra, an antiretroviral, but that the company would continue to negotiate in good faith.

- read this article in The New York Times for more

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.